New vaccine aims to boost TB treatment and prevent relapse
NCT ID NCT06205589
First seen Nov 13, 2025 · Last updated May 10, 2026 · Updated 23 times
Summary
This study tests an experimental vaccine called ID93+GLA-SE in 1,500 people with rifampicin-susceptible pulmonary TB, including those living with HIV. Participants receive the vaccine or a placebo while on standard TB treatment. Researchers want to see if the vaccine is safe, boosts the immune system, and helps prevent poor outcomes like treatment failure or TB coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, PULMONARY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.